ELAN Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Elanco Animal Health (NYSE: ELAN)
›
Elanco Animal Health (NYSE: ELAN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 9,400 employees.
The shares were at 26.29 USD on 19 November 2026, up 24.7% over 52 weeks. Its 52-week range is 19.40 USD to 27.98 USD: the price is 6.0% below the high and 35.5% above the low.
Its market capitalisation is 13.14B USD.
Elanco Animal Health reports return on equity of -3.5%, an operating margin of 7.7% and revenue up 11.3% year over year.
Its debt exceeds its cash by 3.55B USD, a debt-to-equity ratio of 0.61. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 31.15 USD is 18.5% above the current price. The next earnings report is expected on 23 February 2027.